| Title |
The growth arrest-specific transcript 5 (GAS5): a pivotal tumor suppressor long noncoding RNA in human cancers
|
|---|---|
| Published in |
Tumor Biology, December 2015
|
| DOI | 10.1007/s13277-015-4521-9 |
| Pubmed ID | |
| Authors |
Chenhui Ma, Xuefei Shi, Qingqing Zhu, Qian Li, Yafang Liu, Yanwen Yao, Yong Song |
| Abstract |
Long noncoding RNAs (lncRNAs), which refer to a group of RNAs with length more than 200 nucleotides and limited protein-coding potential, play a widespread role in regulating biological processes, such as cell differentiation, proliferation, apoptosis, and migration. LncRNAs are dysregulated in multiple cancers, playing an either oncogenic or tumor-suppressive role. LncRNA GAS5 is a recently identified tumor suppressor involved in several cancers, like breast cancer, prostate cancer, lung cancer, and colorectal cancer. The low-expression pattern confers tumor cells elevated capacity of proliferation and predicts poorer prognosis. Existing studies mirror that lncRNA GAS5 promises to be a novel diagnostic biomarker, therapy target, as well as prognostic biomarker. In this review, we will summarize the current knowledge about this vital lncRNA, from its discovery, characteristics, and biological function to molecular mechanism in various neoplasms. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 60 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 23% |
| Student > Postgraduate | 7 | 12% |
| Researcher | 6 | 10% |
| Student > Master | 5 | 8% |
| Student > Doctoral Student | 4 | 7% |
| Other | 13 | 22% |
| Unknown | 11 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 18 | 30% |
| Agricultural and Biological Sciences | 12 | 20% |
| Medicine and Dentistry | 9 | 15% |
| Immunology and Microbiology | 2 | 3% |
| Neuroscience | 2 | 3% |
| Other | 4 | 7% |
| Unknown | 13 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2015.
All research outputs
#19,054,237
of 23,613,071 outputs
Outputs from Tumor Biology
#1,389
of 2,614 outputs
Outputs of similar age
#283,725
of 390,762 outputs
Outputs of similar age from Tumor Biology
#128
of 321 outputs
Altmetric has tracked 23,613,071 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,614 research outputs from this source. They receive a mean Attention Score of 2.4. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 390,762 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 321 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.